The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic ...

Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...

Purdue researchers identify the PACT protein as a potential target for triple-negative breast cancer, opening new paths for future treatments.

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

Louisiana is making strides in breast cancer research, specifically focusing on triple-negative breast cancer. This type of cancer is known for occurring at an earlier age, spreading ...

The medication is really taking care of business. A pair of new Canadian clinical trials show poop pills can reduce the toxic ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...

A Purdue University team has discovered a new therapeutic target for triple-negative breast cancer. The research, led by Kyle ...